Clinical Trial Update: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial studying the combination of ibrutinib and rituximab in untreated marginal zone lymphoma is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Marginal Zone Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING